ABSTRACT
Lysophosphatidic acid (LPA) exerts various biological activities through six characterized G protein-coupled receptors (LPA1-6 ). While LPA-LPA1 signaling contributes toward the demyelination and retraction of C-fiber and induces neuropathic pain, the effects of LPA-LPA1 signaling on acute nociceptive pain is uncertain. This study investigated the role of LPA-LPA1 signaling in acute nociceptive pain using the formalin test. The pharmacological inhibition of the LPA-LPA1 axis significantly attenuated formalin-induced nociceptive behavior. The LPA1 mRNA was expressed in satellite glial cells (SGCs) in dorsal root ganglion (DRG) and was particularly abundant in SGCs surrounding large DRG neurons, which express neurofilament 200. Treatment with LPA1/3 receptor (LPA1/3 ) antagonist inhibited the upregulation of glial markers and inflammatory cytokines in DRG following formalin injection. The LPA1/3 antagonist also attenuated phosphorylation of extracellular signal-regulated kinase, especially in SGCs and cyclic AMP response element-binding protein in the dorsal horn following formalin injection. LPA amounts after formalin injection to the footpad were quantified by liquid chromatography/tandem mass spectrometry, and LPA levels were found to be increased in the innervated DRGs. Our results indicate that LPA produced in the innervated DRGs promotes the activation of SGCs through LPA1 , increases the sensitivity of primary neurons, and modulates pain behavior. These results facilitate our understanding of the pathology of acute nociceptive pain and demonstrate the possibility of the LPA1 on SGCs as a novel target for acute pain control.
Subject(s)
Isoxazoles/pharmacology , Lysophospholipids/metabolism , Neuroglia/drug effects , Nociceptive Pain/prevention & control , Propionates/pharmacology , Receptors, Lysophosphatidic Acid/antagonists & inhibitors , Animals , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Female , Ganglia, Spinal , Male , Mice , Mice, Inbred C57BL , Neuroglia/metabolism , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Nociceptive Pain/pathology , Phosphorylation , Signal TransductionABSTRACT
Whether pinocembrin (PCN) could be used to alleviate hip fracture-induced pain is investigated in this research. Aged rats with hip fractures were treated with vehicle or 80 mg/kg/day PCN from week 3 to week 4. Then, hind paw mechanical allodynia, unweighting, warmth, and thickness were measured. The microglia and astrocytes activation and proliferation markers in the spinal dorsal horn were detected with real-time PCR and immunofluorescence staining. The relative expression of substance P and its receptor, tachykinin receptor 1 (Tacr1), was detected with enzyme-linked immunosorbent assay (ELISA) and Western blots. The antinociceptive effect of Tacr1 inhibitor LY303870 was also testified. PCN alleviated hip fracture-induced hind paw nociceptive (allodynia and unweighting) and vascular changes (warmth and thickness) in aged rats with diminished microglia and astrocytes activation and proliferation in the spinal dorsal horn. Upregulated substance P and Tacr1 were induced after hip fracture, which could be reversed by PCN treatment. Furthermore, LY303870 treatment partially reversed both spinal nociceptive sensitization and vascular changes after hip fracture. Substance P signaling contributes to the nociceptive and vascular changes observed in the hip fracture, which could be alleviated by PCN.NEW & NOTEWORTHY Substance P signaling contributes to the nociceptive and vascular changes observed in hip fracture, which could be alleviated by PCN.
Subject(s)
Aging , Flavanones/pharmacology , Hip Fractures/drug therapy , Neurokinin-1 Receptor Antagonists/pharmacology , Pain/drug therapy , Substance P/drug effects , Animals , Disease Models, Animal , Flavanones/administration & dosage , Hip Fractures/complications , Hip Fractures/metabolism , Indoles/pharmacology , Male , Neurokinin-1 Receptor Antagonists/administration & dosage , Nociceptive Pain/drug therapy , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Pain/etiology , Pain/metabolism , Piperidines/pharmacology , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effectsABSTRACT
The recently identified molecule P7C3 has been highlighted in the field of pain research. We examined the effect of intrathecal P7C3 in tissue injury pain evoked by formalin injection and determined the role of the GABA system in the activity of P7C3 at the spinal level. Male Sprague-Dawley rats with intrathecal catheters implanted for experimental drug delivery were studied. The effects of intrathecal P7C3 and nicotinamide phosphoribosyltransferase (NAMPT) administered 10 min before the formalin injection were examined. Animals were pretreated with bicuculline, a GABA-A receptor antagonist; saclofen, a GABA-B receptor antagonist; L-allylglycine, a glutamic acid decarboxylase (GAD) blocker; and CHS 828, an NAMPT inhibitor; to observe involvement in the effects of P7C3. The effects of P7C3 alone and the mixture of P7C3 with GABA receptor antagonists on KCl-induced calcium transients were examined in rat dorsal root ganglion (DRG) neurons. The expression of GAD and the concentration of GABA in the spinal cord were evaluated. Intrathecal P7C3 and NAMPT produced an antinociceptive effect in the formalin test. Intrathecal bicuculline, saclofen, L-allylglycine, and CHS 828 reversed the antinociception of P7C3 in both phases. P7C3 decreased the KCl-induced calcium transients in DRG neurons. Both bicuculline and saclofen reversed the blocking effect of P7C3. The levels of GAD expression and GABA concentration decreased after formalin injection and were increased by P7C3. These results suggest that P7C3 increases GAD activity and then increases the GABA concentration in the spinal cord, which in turn may act on GABA receptors causing the antinociceptive effect against pain evoked by formalin injection.
Subject(s)
Analgesics/administration & dosage , Carbazoles/administration & dosage , Nociceptive Pain/drug therapy , Pain Threshold/drug effects , Spinal Cord/drug effects , gamma-Aminobutyric Acid/metabolism , Animals , Calcium Signaling , Disease Models, Animal , Formaldehyde , Glutamate Decarboxylase/metabolism , Inflammation/chemically induced , Injections, Spinal , Male , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Nociceptive Pain/physiopathology , Rats, Sprague-Dawley , Spinal Cord/metabolism , Spinal Cord/physiopathologyABSTRACT
The success of antiretroviral therapy (ART) has improved the survival of HIV-infected patients significantly. However, significant numbers of patients on ART whose HIV disease is well controlled show peripheral sensory neuropathy (PSN), suggesting that ART may cause PSN. Although the nucleoside reverse transcriptase inhibitors (NRTIs), one of the vital components of ART, are thought to contribute to PSN, the mechanisms underlying the PSN induced by NRTIs are unclear. In this study, we developed a Drosophila model of NRTI-induced PSN that recapitulates the salient features observed in patients undergoing ART: PSN and nociceptive hypersensitivity. Furthermore, our data demonstrate that pathways known to suppress PSN induced by chemotherapeutic drugs are ineffective in suppressing the PSN or nociception induced by NRTIs. Instead, we found that increased dynamics of a peripheral sensory neuron may possibly underlie NRTI-induced PSN and nociception. Our model provides a solid platform in which to investigate further mechanisms of ART-induced PSN and nociceptive hypersensitivity.This article has an associated First Person interview with the first author of the paper.
Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , Nociceptive Pain/etiology , Peripheral Nervous System Diseases/etiology , Animals , Anti-HIV Agents/adverse effects , Anti-Retroviral Agents/adverse effects , Disease Models, Animal , Drosophila , HIV Infections/complications , HIV Infections/drug therapy , Humans , Nociceptive Pain/diagnosis , Peripheral Nervous System Diseases/diagnosis , Sensory Receptor CellsABSTRACT
The pro-resolving mechanism is a recently described endogenous process that controls inflammation. The present study evaluated components of this mechanism, including annexin 1 (ANXA1) and the formyl peptide receptor 2/ALX (FPR2/ALX) receptor, in the antihyperalgesic effect induced by electroacupuncture (EA) in an animal model of persistent peripheral inflammation. Male Swiss mice underwent intraplantar (i.pl.) injection with complete Freund's adjuvant (CFA). Mechanical hyperalgesia was assessed with von Frey monofilaments. Animals were treated with EA (2-10 Hz, ST36-SP6) or subcutaneous BML-111 injection (FPR2/ALX agonist) for 5 consecutive days. In a separate set of experiments, on the first and fifth days after CFA injection, animals received i.pl. WRW4 (FPR2/ALX antagonist) or naloxone (non-selective opioid receptor antagonist) before EA or BML-111 injection. Paw protein levels of FPR2/ALX and ANXA1 were evaluated on the second day after CFA injection by western blotting technique. EA and BML-111 reduced mechanical hyperalgesia. I.pl. naloxone or WRW4 prevented the antihyperalgesic effect induced by either EA or BML-111. EA increased ANXA1 but did not alter FPR2/ALX receptor levels in the paw. Furthermore, i.pl. pretreatment with WRW4 prevented the increase of ANXA1 levels induced by EA. This work demonstrates that the EA antihyperalgesic effect on inflammatory pain involves the ANXA1/FPR2/ALX pro-resolution pathway. This effect appears to be triggered by the activation of FPR2/ALX receptors and crosstalk communication with the opioid system.
Subject(s)
Annexin A1/metabolism , Electroacupuncture/methods , Hyperalgesia/therapy , Nociceptive Pain/therapy , Receptors, Formyl Peptide/metabolism , Receptors, Opioid/metabolism , Animals , Freund's Adjuvant/toxicity , Heptanoic Acids/pharmacology , Hyperalgesia/etiology , Hyperalgesia/metabolism , Male , Mice , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Nociception/drug effects , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Receptors, Formyl Peptide/antagonists & inhibitors , Receptors, Opioid/therapeutic useABSTRACT
Pain contributes substantially to reduced quality of life in individuals living with hidradenitis suppurativa (HS). Although improved understanding of HS pathogenesis and treatment has resulted in improved evidence-based HS management guidelines, comprehensive pain management guidelines have yet to be developed. Few HS-specific data exist to guide pharmacologic analgesia; however, recognizing HS pain as either acute or chronic and predominantly nociceptive (aching and gnawing pain due to tissue damage) versus neuropathic (burning-type pain due to somatosensory nervous system dysfunction) provides a conceptual framework for applying outside pain management practices to HS management. This article incorporates the best available evidence from the HS and pain literature to propose an HS pain algorithm that integrates psychological, pharmacologic, and complementary and alternative treatment modalities.
Subject(s)
Algorithms , Hidradenitis Suppurativa/complications , Neuralgia/therapy , Nociceptive Pain/therapy , Pain Management/methods , Analgesics/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Chronic Pain/etiology , Chronic Pain/psychology , Chronic Pain/therapy , Cognitive Behavioral Therapy , Complementary Therapies , Depression/etiology , Depression/therapy , Humans , Neuralgia/etiology , Neuralgia/psychology , Neurotransmitter Agents/therapeutic use , Nociceptive Pain/etiology , Nociceptive Pain/psychology , Practice Guidelines as TopicABSTRACT
The increased use of opioids to treat pain has led to a dramatic increase in opioid abuse. Our previous data indicate that pain may facilitate the development of opioid abuse by increasing the magnitude and duration of opioid withdrawal. The present study tested the hypothesis that social housing would facilitate recovery of activity depressed by pain and opioid withdrawal. Male Sprague Dawley rats were housed either in pairs or alone and then moved to a cage with a running wheel for 6 h daily to assess pain- and opioid withdrawal-induced depression of wheel running. Rats were implanted with two morphine (75 mg each) or placebo pellets to induce opioid dependence and were simultaneously injected with Complete Freund's Adjuvant or saline into the right hind paw to induce persistent inflammatory pain. Hind paw inflammation depressed wheel running whether rats were implanted with a morphine or placebo pellet. Pair-housed rats showed greater recovery of wheel running than individually housed rats. Spontaneous morphine withdrawal precipitated by removal of the morphine pellets caused a reduction in wheel running that was greater in rats with hind paw inflammation compared to pain free rats. Social housing facilitated recovery from withdrawal in rats with hind paw inflammation, but slowed recovery in pain free rats. These data suggest that social housing facilitates recovery by reducing pain both before and during opioid withdrawal. Our findings are consistent with previous studies showing that social buffering reduces pain-evoked responses.
Subject(s)
Analgesics, Opioid/administration & dosage , Depression/physiopathology , Housing, Animal , Locomotion/physiology , Morphine/administration & dosage , Nociceptive Pain/physiopathology , Opioid-Related Disorders/physiopathology , Social Behavior , Substance Withdrawal Syndrome/physiopathology , Animals , Behavior, Animal/physiology , Depression/rehabilitation , Freund's Adjuvant , Inflammation/chemically induced , Inflammation/complications , Male , Nociceptive Pain/etiology , Nociceptive Pain/rehabilitation , Rats , Rats, Sprague-Dawley , Substance Withdrawal Syndrome/rehabilitationABSTRACT
Considering the many biological activities of nitric oxide (NO), some lines of research focused on the modulation of these activities through the provision of this mediator by designing and synthesizing compounds coupled with an NO donor group. Thus, the objectives of the present study were to carry out an electrochemical investigation of the nitrooxy compound 4-((nitrooxy) methyl)-3-nitrobenzoic acid (1) and evaluate its activities and putative mechanisms in experimental models of pain and inflammation. Voltammetric studies performed in aprotic medium (mimetic of membranes) showed important electrochemical reduction mechanisms: nitroaromatic reduction, self-protonation, and finally reductive elimination, which leads to nitrate release. Systemic administration of the nitrooxy compound (1) inhibited the nociceptive response induced by heat and the tactile hypersensitivity and paw edema induced by carrageenan in mice. The activities in the models of inflammatory pain and edema were associated with reduced neutrophil recruitment and production of inflammatory cytokines, such as interleukin (IL)-1ß, IL-6, tumor necrosis factor-α and CXCL-1, and increased production of IL-10. Concluding, electrochemical analysis revealed unequivocally that electron transfer at the nitro group of the nitrooxy compound (1) results in the cleavage of the organic nitrate, potentially resulting in the generation of NO. This electrochemical mechanism may be compared to a biochemical electron-transfer mediated nitrate release that, by appropriate in vivo bioreduction (enzymatic or not) would lead to NO production. Compound (1) exhibits activities in models of inflammatory pain and edema that may be due to reduced recruitment of neutrophils and production of inflammatory cytokines and increased production of IL-10. These results reinforce the interest in the investigation of NO donor compounds as candidates for analgesic and anti-inflammatory drugs.
Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Inflammation/prevention & control , Nitrates/blood , Nitric Oxide Donors/pharmacology , Nociceptive Pain/prevention & control , Pain Threshold/drug effects , Analgesics/blood , Animals , Anti-Inflammatory Agents/blood , Carrageenan , Cytokines/blood , Disease Models, Animal , Electrochemistry , Female , Hot Temperature , Inflammation/blood , Inflammation/chemically induced , Inflammation Mediators/blood , Mice , Nitric Oxide Donors/blood , Nociceptive Pain/blood , Nociceptive Pain/etiology , Nociceptive Pain/physiopathologyABSTRACT
Plants are vital in drug discovery, since many safe and bioactive molecules have been discovered from plants in past, hence this study was designed to evaluate analgesic, anti-inflammatory and toxic effects of Cucumis melo and Citrullus lanatus. Seeds of these plants were selected due to their traditional value for medicinal use. Analgesic activity was determined in mice by Eddy's Hot plate and tail flick method, while anti-inflammatory activity was evaluated by hind paw edema method. Both seed extracts produced highly significant analgesic effects comparable to standard drugs at all three doses by both methods. The extract of C. lanatus showed significant anti-inflammatory activity at 100 mg while showed highly significant activity at 200 mg between 3 to 24 hours as compared to standard drugs. Both extracts did not reveal any mortality up to 1000mg/kg, while there was also no change in normal the gross behavior pattern of the animals at the dose of 50 and 100mg/kg, however there was increase in passivity, sedation and startle response at 200mg/kg. Analgesic and anti-inflammatory effects of extracts may be due to presence of cucurbitacin A, B or E in both seeds which are thought to inhibit COX 2. Results indicate that seeds of C. melo and C. lanatus may be effectively used as adjuvant analgesic and anti-inflammatory agents in situation of chronic pain and inflammation.
Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Citrullus , Cucumis melo , Inflammation/prevention & control , Nociceptive Pain/prevention & control , Plant Extracts/pharmacology , Analgesics/isolation & purification , Analgesics/toxicity , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/toxicity , Carrageenan , Citrullus/chemistry , Citrullus/toxicity , Cucumis melo/chemistry , Cucumis melo/toxicity , Disease Models, Animal , Dose-Response Relationship, Drug , Ethanol/chemistry , Female , Inflammation/chemically induced , Male , Mice , Nociceptive Pain/etiology , Nociceptive Pain/physiopathology , Pain Threshold/drug effects , Plant Extracts/isolation & purification , Plant Extracts/toxicity , Rats , Seeds , Solvents/chemistryABSTRACT
The adult K/BxN transgenic mouse develops spontaneous autoimmune arthritis with joint remodeling and profound bone loss. We report that both males and females display a severe sustained tactile allodynia which is reduced by gabapentin but not the potent cyclooxygenase inhibitor ketorolac. In dorsal horn, males and females show increased GFAP+ astrocytic cells; however, only males demonstrate an increase in Iba1+ microglia. In dorsal root ganglia (DRG), there is an increase in CGRP+, TH+, and Iba1+ (macrophage) labeling, but no increase in ATF3+ cells. At the ankle there is increased CGRP+, TH+, and GAP-43+ fiber synovial innervation. Thus, based on the changes in dorsal horn, DRG and peripheral innervation, we suggest that the adult K/BxN transgenic arthritic mice display a neuropathic phenotype, an assertion consistent with the analgesic pharmacology seen in this animal. These results indicate the relevance of this model to our understanding of the nociceptive processing which underlies the chronic pain state that evolves secondary to persistent joint inflammation.
Subject(s)
Arthritis, Experimental/complications , Ganglia, Spinal/pathology , Hyperalgesia/pathology , Knee Joint/pathology , Nerve Tissue/pathology , Nociceptive Pain/pathology , Analgesics/pharmacology , Animals , Arthritis, Experimental/physiopathology , Female , Gabapentin/pharmacology , Ganglia, Spinal/drug effects , Hyperalgesia/drug therapy , Hyperalgesia/etiology , Knee Joint/drug effects , Male , Mice , Mice, Transgenic , Nerve Tissue/drug effects , Neuralgia/pathology , Nociceptive Pain/drug therapy , Nociceptive Pain/etiology , PhenotypeABSTRACT
Pain is a distressful experience that can have a major impact on an individual's quality of life. The need for new and better analgesics has been further intensified in light of the current opioid epidemic. Substances obtained from amphibians have been shown to contain bioactive peptides that exert analgesic effects. The genus Phyllomedusa represents an important source of peptides and bioactive components. The aim of this study was to investigate the antinociceptive effects of the skin secretion of Phyllomedusa rohdei in rodent models of pain. The crude skin extract of P. rohdei was tested in different pain models: acetic acid-induced writhing test (mice), formalin test (rats), Von Frey electronic test for hypernociception induced by PGE2 (rats), and hot plate test (mice). Motor-impairing effects were tested using the rota-rod test. The results showed that the skin extract of P. rohdei exerted antinociceptive effects in all pain models tested. Particularly, the highest dose tested of the skin extract decreased acetic acid-induced writhing by 93%, completely blocked formalin-induced nociception both during the acute and inflammatory phases of the test, PGE2-induced hypernociception by 73% and increased latency to paw withdrawal in the hot plate test by 300%. The effects observed in the hot plate test were reversed by pretreatment with selective µ and κ, but not δ, opioid receptor antagonists, indicating a mechanism of action dependent on µ and κ opioid receptors. The results were not influenced by sedative effects. Further studies remain necessary to reveal the specific compounds involved in the antinociceptive effects of P. rohdei skin extract as a new therapeutic tool in pain management.
Subject(s)
Analgesics/pharmacology , Anura/metabolism , Nociceptive Pain/prevention & control , Skin/metabolism , Analgesics/metabolism , Animals , Behavior, Animal/drug effects , Disease Models, Animal , Male , Mice , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Nociceptive Pain/physiopathology , Pain Threshold/drug effects , Rats, Wistar , Receptors, Opioid, delta/metabolism , Receptors, Opioid, mu/metabolism , Secretory PathwayABSTRACT
Ultrasound is an invaluable physical modality widely used for diagnosis and therapy in humans and animals. It is noninvasive, atraumatic, and may be used repeatedly. As a therapeutic tool, ultrasound has been in use for some 6 decades. Therapeutic ultrasound (TUS) is used for the treatment of musculoskeletal disorders, including acute soft tissue injuries, overuse syndromes, as well as chronic orthopedic and rheumatologic conditions. The aim of this review was to investigate the clinical effectiveness of TUS in musculoskeletal acute and chronic pain, mainly through the control of inflammation and the promotion of soft tissue injury healing. Based on the evidence presented, TUS is clinically effective in some musculoskeletal soft tissue pain conditions, but due to conflicting results in some studies, no specific positive recommendations can be made, nor does it permit exclusion of TUS from clinical practice. In phonophoresis, TUS plays a significant role, without reported adverse effects. There is scope for improving the evidence base with better designed studies.
Subject(s)
Musculoskeletal Diseases , Nociceptive Pain/therapy , Soft Tissue Injuries/therapy , Ultrasonic Therapy/methods , Humans , Musculoskeletal Diseases/classification , Musculoskeletal Diseases/physiopathology , Musculoskeletal Diseases/therapy , Nociceptive Pain/etiology , Treatment OutcomeSubject(s)
Disruptive, Impulse Control, and Conduct Disorders/etiology , Disruptive, Impulse Control, and Conduct Disorders/physiopathology , Impulsive Behavior/physiology , Pain/etiology , Parkinson Disease/complications , Aged , Female , Humans , Male , Middle Aged , Neuralgia/etiology , Nociceptive Pain/etiologyABSTRACT
BACKGROUND: After pylorus-preserving pancreaticoduodenectomy (PPPD), incision and suture of the abdominal muscles cause inflammatory changes and elicit somatic pain that deteriorates the quality of life. There have been no previous reports on needle electrical twitch obtaining intramuscular stimulation (NETOIMS) in abdominal open operation; this study aimed to apply NETOIMS for postoperative somatic pain in patients undergoing PPPD as a new treatment modality for pain control. METHODS: Between June 2018 and January 2019, 44 patients who underwent PPPD were randomly assigned to a control group and the NETOIMS group. The NETOIMS group received NETOIMS in the transverse abdominis muscle under ultrasound guidance right after operation under general anesthesia. The pain score (visual analog scale), peak cough flow (PCF), and gait speed were repetitively measured from 1 day before operation to 2 weeks after discharge as scheduled. Data were analyzed by the linear mixed model and repeated-measures analysis of variance. RESULTS: Of the 44 patients recruited, data from 38 patients were finally analyzed. The pain scores were significantly lower in the NETOIMS group after PPPD (p = 0.01). Although the PCF at each measuring time point did not show inter-group difference (p = 0.20), improvement of PCF from the second day after operation to discharge was greater (p = 0.02) and gait speed improved significantly faster (p < 0.01) in the NETOIMS group than in the control group. CONCLUSIONS: NETOIMS helps in rapid reduction of postoperative somatic pain developed after PPPD and in improvement of PCF and gait speed.
Subject(s)
Electric Stimulation Therapy/methods , Nociceptive Pain/etiology , Nociceptive Pain/therapy , Pain, Postoperative/etiology , Pain, Postoperative/therapy , Pancreaticoduodenectomy/adverse effects , Aged , Double-Blind Method , Female , Humans , Male , Middle AgedABSTRACT
ETHNOPHARMACOLOGY RELEVANCE: Schinus terebinthifolia Raddi leaves have been used in folk medicine due to several properties, including antitumor and analgesic effects. The variable efficacy and adverse effects of analgesic drugs have motivated the search for novel antinociceptive agents. It has been reported that the S. terebinthifolia leaf lectin (SteLL) has antitumor activity against sarcoma 180 in mice. AIM OF THE STUDY: This work aimed to evaluate whether SteLL would reduce cancer pain using an orthotopic tumor model. MATERIALS AND METHODS: A sarcoma 180 cell suspension was inoculated into the right hind paws of mice, and the treatments (150 mM NaCl, negative control; 10 mg/kg morphine, positive control; or SteLL at 1 and 2 mg/kg) were administered intraperitoneally 24 h after cell inoculation up to 14 days. Spontaneous nociception, mechanical hyperalgesia, and hot-plate tests were performed. Further, the volume and weight of the tumor-bearing paws were measured. RESULTS: SteLL (2 mg/kg) improved limb use during ambulation. The lectin (1 and 2 mg/kg) also inhibited mechanical hyperalgesia and increased the latency time during the hot-plate test. Naloxone was found to reverse this effect, indicating the involvement of opioid receptors. The tumor-bearing paws of mice treated with SteLL exhibited lower volume and weight. CONCLUSION: SteLL reduced hyperalgesia due to sarcoma 180 in the paws of mice, and this effect can be related to its antitumor action.
Subject(s)
Anacardiaceae , Analgesics/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Cancer Pain/prevention & control , Hyperalgesia/prevention & control , Nociceptive Pain/prevention & control , Plant Leaves , Plant Lectins/pharmacology , Sarcoma 180/drug therapy , Anacardiaceae/chemistry , Analgesics/isolation & purification , Animals , Antineoplastic Agents, Phytogenic/isolation & purification , Cancer Pain/etiology , Cancer Pain/metabolism , Cancer Pain/physiopathology , Female , Hyperalgesia/etiology , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Mice , Nociception/drug effects , Nociceptive Pain/etiology , Nociceptive Pain/metabolism , Nociceptive Pain/physiopathology , Pain Threshold/drug effects , Plant Leaves/chemistry , Plant Lectins/isolation & purification , Reaction Time/drug effects , Receptors, Opioid/metabolism , Sarcoma 180/complications , Sarcoma 180/pathology , Signal Transduction , Time FactorsABSTRACT
BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment choice for peritoneal cancer. However, patients commonly suffer from severe postoperative pain. The pathophysiology of postoperative pain is considered to be from both nociceptive and neuropathic origins. MAIN BODY: The recent advances on the etiology of postoperative pain after CRS + HIPEC treatment were described, and the treatment strategy and outcomes were summarized. CONCLUSION: Conventional analgesics could provide short-term symptomatic relief. Thoracic epidural analgesia combined with opioids administration could be an effective treatment choice. In addition, a transversus abdominis plane block could also be an alternative option, although further studies should be performed.
Subject(s)
Pain Management , Pain, Postoperative/physiopathology , Pain, Postoperative/therapy , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/surgery , Analgesics/therapeutic use , Combined Modality Therapy/adverse effects , Cytoreduction Surgical Procedures/adverse effects , Hyperthermic Intraperitoneal Chemotherapy/adverse effects , Nerve Block , Neuralgia/etiology , Neuralgia/physiopathology , Neuralgia/therapy , Nociceptive Pain/etiology , Nociceptive Pain/physiopathology , Nociceptive Pain/therapy , Pain, Postoperative/etiology , Peritoneal Neoplasms/pathologyABSTRACT
Various types of acute/chronic nociceptive stimuli cause neuroendocrine responses such as activation of the hypothalamo-neurohypophysial [oxytocin (OXT) and arginine vasopressin (AVP)] system and hypothalamo-pituitary adrenal (HPA) axis. Chronic multiple-arthritis activates the OXT/AVP system, but the effects of acute mono-arthritis on the OXT/AVP system in the same animals has not been simultaneously evaluated. Further, AVP, not corticotropin-releasing hormone (CRH), predominantly activates the HPA axis in chronic multiple-arthritis, but the participation of AVP in HPA axis activation in acute mono-arthritis remains unknown. Therefore, we aimed to simultaneously evaluate the effects of acute mono-arthritis on the activity of the OXT/AVP system and the HPA axis. In the present study, we used an acute mono-arthritic model induced by intra-articular injection of carrageenan in a single knee joint of adult male Wistar rats. Acute mono-arthritis was confirmed by a significant increase in knee diameter in the carrageenan-injected knee and a significant decrease in the mechanical nociceptive threshold in the ipsilateral hind paw. Immunohistochemical analysis revealed that the number of Fos-immunoreactive (ir) cells in the ipsilateral lamina I-II of the dorsal horn was significantly increased, and the percentage of OXT-ir and AVP-ir neurons expressing Fos-ir in both sides of the supraoptic (SON) and paraventricular nuclei (PVN) was increased in acute mono-arthritic rats. in situ hybridization histochemistry revealed that levels of OXT mRNA and AVP hnRNA in the SON and PVN, CRH mRNA in the PVN, and proopiomelanocortin mRNA in the anterior pituitary were also significantly increased in acute mono-arthritic rats. Further, plasma OXT, AVP, and corticosterone levels were significantly increased in acute mono-arthritic rats. These results suggest that acute mono-arthritis activates ipsilateral nociceptive afferent pathways at the spinal level and causes simultaneous and integrative activation of the OXT/AVP system. In addition, the HPA axis is activated by both AVP and CRH in acute mono-arthritis with a distinct pattern compared to that in chronic multiple-arthritis.
Subject(s)
Arthritis/physiopathology , Hypothalamo-Hypophyseal System/physiopathology , Pituitary-Adrenal System/physiopathology , Acute Disease , Afferent Pathways/physiology , Animals , Arginine Vasopressin/blood , Arginine Vasopressin/genetics , Arthritis/genetics , Arthritis/metabolism , Arthritis/pathology , Corticotropin-Releasing Hormone/blood , Corticotropin-Releasing Hormone/genetics , Hypothalamo-Hypophyseal System/metabolism , Hypothalamo-Hypophyseal System/pathology , Male , Neurons/physiology , Nociceptive Pain/etiology , Nociceptive Pain/genetics , Nociceptive Pain/metabolism , Nociceptive Pain/physiopathology , Osteoarthritis, Knee/genetics , Osteoarthritis, Knee/metabolism , Osteoarthritis, Knee/pathology , Osteoarthritis, Knee/physiopathology , Oxytocin/blood , Oxytocin/genetics , Pituitary-Adrenal System/metabolism , Pituitary-Adrenal System/pathology , Pro-Opiomelanocortin/blood , Pro-Opiomelanocortin/genetics , Rats , Rats, WistarABSTRACT
BACKGROUND: The effects of environmental changes on the somato-sensory system during long-distance air ambulance flights need to be further investigated. Changes in nociceptive capacity are conceivable in light of previous studies performed under related environmental settings. We used standardized somato-sensory testing to investigate nociception in healthy volunteers during air-ambulance flights. METHODS: Twenty-five healthy individuals were submitted to a test compilation analogous to the quantitative sensory testing battery-performed during actual air-ambulance flights. Measurements were paired around the major changes of external factors during take-off/climb and descent/landing. Bland-Altman-Plots were calculated to identify possible systemic effects. RESULTS: Bland-Altman-analyses suggest that the thresholds of stimulus detection and pain as well as above-threshold pain along critical waypoints of travel are not subject to systemic effects but instead demonstrate random variations. CONCLUSIONS: We provide a novel description of a real-life experimental setup and demonstrate the general feasibility of performing somato-sensory testing during ambulance flights. No systematic effects on the nociception of healthy individuals were apparent from our data. Our findings open up the possibility of future investigations into potential effects of ambulance flights on patients suffering acute or chronic pain.
Subject(s)
Air Ambulances , Nociception , Nociceptive Pain/etiology , Travel-Related Illness , Adult , Air Travel , Healthy Volunteers , Humans , Male , Middle Aged , Pain ThresholdABSTRACT
Managing severe acute nociceptive pain in buprenorphine-maintained individuals for opioid use disorder management is challenging owing to the high affinity and very slow dissociation of buprenorphine from µ-opioid receptors that hinders the use of full agonist opioid analgesics. In a translational approach, the aim of this study was to use an animal setting to investigate the effects of a chronic high dose of buprenorphine treatment on nociceptive thresholds before and after applying a severe acute nociceptive traumatic surgery stimulus and to screen postoperative pharmacological analgesic strategies. A chronic treatment of mice with a high dose of buprenorphine (BUP HD, 2 × 200 µg/kg/day; i.p.) revealed significant mechanical allodynia. One and two days after having discontinued buprenorphine administration and having induced a severe nociceptive acute pain by a closed tibial fracture, acute administration of morphine at a dose which has analgesic effects in absence of pretreatment (4.5 mg/kg; i.p.), was ineffective to reduce pain in the BUP HD group. However, mimicking multimodal analgesia strategy used in human postoperative context, the combination of morphine (administered at the same dose) with a NMDA receptor antagonist (ketamine) or an NSAID (ketoprofen) produced antinociceptive responses in these animals. The mouse model of closed tibial fracture could be useful to identify analgesic strategies of postoperative pain for patients with chronic exposure to opioids and suffering from hyperalgesia.
Subject(s)
Acute Pain/drug therapy , Analgesics/pharmacology , Buprenorphine/adverse effects , Hyperalgesia/drug therapy , Narcotic Antagonists/adverse effects , Nociceptive Pain/drug therapy , Acute Pain/diagnosis , Acute Pain/etiology , Analgesics/therapeutic use , Animals , Buprenorphine/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination/methods , Humans , Hyperalgesia/chemically induced , Hyperalgesia/diagnosis , Ketamine/pharmacology , Ketamine/therapeutic use , Ketoprofen/pharmacology , Ketoprofen/therapeutic use , Male , Mice , Morphine/pharmacology , Morphine/therapeutic use , Narcotic Antagonists/administration & dosage , Nociception/drug effects , Nociceptive Pain/diagnosis , Nociceptive Pain/etiology , Opioid-Related Disorders/drug therapy , Pain Management/methods , Pain Measurement , Pain Threshold/drug effects , Tibial Fractures/complicationsABSTRACT
OBJECTIVE: Pain is one of the most frequent nonmotor impairments in Parkinson's disease (PD) and is hypothesized to be associated with altered nociceptive pain processing. Our aims were to investigate differences in widespread pressure pain sensitivity between PD patients with and without pain and healthy controls and to assess the relationship of health-related quality of life and sleep quality with pressure pain sensitivity. METHODS: Nineteen PD patients with pain (12 men, age = 68 ± 9 years), 19 PD patients without pain (11 men, age = 69 ± 8 years), and 19 matched controls participated. Pressure pain thresholds (PPTs) were assessed bilaterally over the cervical spine, the second metacarpal, and the tibialis anterior by an assessor blinded to the subject's condition. Patients were assessed in a dopamine-medicated (ON) state. Pain intensity (numerical pain rating scale, 0-10), health-related quality of life (39-item Parkinson's Disease Questionnaire), and sleep quality (Pittsburgh Sleep Quality Index) were also assessed. RESULTS: No significant differences existed between PD patients, with or without pain, and healthy controls on PPTs over the cervical spine, the second metacarpal, or the tibialis anterior muscle (all P > 0.3). PPTs were lower in females than in males in all groups (P < 0.01). In PD patients with pain, worse quality of sleep was associated with higher widespread pressure pain sensitivity (-0.607 < r < -0.535, P < 0.05). No other significant association was observed. CONCLUSIONS: This study revealed no differences in widespread pressure hyperalgesia between PD patients with or without pain (ON state) and controls. Although dopamine may modulate pain responses, other mechanisms seems to also be implicated in altered nociceptive pain processing in patients with PD.